MedPath

Evaluating the effects of omega-3 on weight and depressio

Not Applicable
Conditions
Condition 1: Mild Depression. Condition 2: Moderate depression. Condition 3: Obseity.
Moderate depressive episode Four or more of the above symptoms are usually present and the patient is likely to have great difficulty in continuing with ordinary activities.
Mild depressive episode Two or three of the above symptoms are usually present. The patient is usually distressed by these but will probably be able to continue with most activities.
Obesity due to excess calories
Registration Number
IRCT2014053016465N3
Lead Sponsor
Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
50
Inclusion Criteria

Age 18 to 50 years; females; Body Mass Index above 25; patients with mild (minor) depression based on semi- structured diagnostic interview by a psychiatrist; to sign a consent form

Exclusion Criteria

Those who are taking antidepressants; severe (major) depression; psychotic depression or have suicidal thoughts; use of anti-inflammatory glucocorticoids, and steroids; those who take medicines to reduce appetite or weight; those with diabetes who are taking medications or insulin; those with heart disease or hypercholesterolemia who are taking medication (statins, fibrates, diuretics); those how are taking oral anti-inflammatory drugs corticosteroids or any drug that causes weight loss or gain; taking hormonal contraceptives; pregnancy and lactation; menopause; severe mental disorder; schizophrenia and bipolar; hypothyroidism; exercise professionals; allergic to fish (due to Omega-3 supplements); those with special diets such as the diets for kidney disorders.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Weight. Timepoint: At baseline and at weeks 2, 4, 8 and 12 after the bigining of the study. Method of measurement: Standard scales Seca.;Body Mass Index. Timepoint: At baseline and at weeks 2, 4, 8 and 12 after the bigining of the study. Method of measurement: kg/(m)2.;Depression. Timepoint: At baseline and at weeks 2, 4, 8 and 12 after the bigining of the study. Method of measurement: Hamilton rating scale for depression.
Secondary Outcome Measures
NameTimeMethod
Central fat mass. Timepoint: At baseline and at weeks 2, 4, 8 and 12 after the bigining. Method of measurement: Bioelectrical impadance.
© Copyright 2025. All Rights Reserved by MedPath